abacavir sulfate / dolutegravir sodium / lamivudine

This medicine is authorised for use in the European Union.


Triumeq is a medicine for treating infection with human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). It is used in adults, adolescents and children who weigh at least 14 kg.

Triumeq contains three active substances: dolutegravir, abacavir and lamivudine.

This EPAR was last updated on 27/11/2023

Authorisation details

Product details
Agency product number
Active substance
  • dolutegravir sodium
  • lamivudine
  • abacavir (as sulfate)
International non-proprietary name (INN) or common name
abacavir sulfate / dolutegravir sodium / lamivudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
ViiV Healthcare B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Van Asch van Wijckstraat 55 H
3811 LP Amersfoort
The Netherlands

Product information

15/11/2023 Triumeq - EMEA/H/C/002754 - PSUSA/00010075/202301

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents in Triumeq.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating
4 ratings